Dalbergia ecastaphyllum leaf extracts: in vitro inhibitory potential against enzymes related to metabolic syndrome, inflammation and neurodegenerative diseases
For the first time, the anti-hemolytic activity and the enzyme inhibitory activities of
Dalbergia ecastaphyllum leaves extracts were tested against α-amylase, α-glucosidase, lipase,
acetylcholinesterase, butyrylcholinesterase, tyrosinase and hyaluronidase. The phenolic profile of the
obtained extracts was also investigated by high-performance liquid chromatography with photodiode
array detection (HPLC-PAD). The extracts showed inhibitory activity against all enzymes evaluated, with
the highest inhibitory activity reported for the enzyme hyaluronidase (28.28 ± 2.43 to 72.19 ± 1.40 μg mL-1).
The obtained extracts also demonstrate anti-hemolytic activity (52.22 ± 1.62 to 71.17 ± 1.82%). Among
the phenolic compounds identified, protocatechuic, vanillic and β-resorcylic acids were the most
abundant (1.13 ± 0.06 to 2.53 ± 0.06, 0.90 ± 0.06 to 2.19 ± 0.06 and 1.03 ± 1.62 to 22.11 ± 1.62 mg L-1,
respectively). In the statistical analysis, a significant correlation was found between the flavonoids
content and all enzymes inhibitory activities. The present study showed that D. ecastaphyllum leaves
extracts may have the potential to be used in the therapeutic treatment of several diseases such as
Alzheimer, Parkinson, type 2 diabetes mellitus, hyperglycemia, and pigmentation, as well as those
associated with oxidative stress.
